United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 4 mg - doxazosin tablets, usp are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin tablets, usp may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin tablets, usp monotherapy. doxazosin tablets, usp provide rapid improvement in symptoms and urinary flow rate in 66 to 71% of patients. sustained improvements with doxazosin tablets, usp were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. doxazosin tablets, usp are indicated for the treatment of hypertension, to lower blood  pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular event

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - doxazosin mesilate - oral tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - doxazosin mesilate - oral tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - doxazosin mesilate - oral tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - doxazosin mesilate - oral tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ivax pharmaceuticals uk ltd - doxazosin mesilate - oral tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ranbaxy (uk) ltd - doxazosin mesilate - oral tablet - 2mg

Australia - English - Department of Health (Therapeutic Goods Administration)

idt australia ltd - doxazosin mesilate, quantity: 9.704 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; indigo carmine aluminium lake; pregelatinised maize starch; iron oxide yellow; magnesium stearate - benign prostatic hyperplasia: for the treatment of both the urinary outflow obstruction and obstuctive and irritative symptoms associated with bph. hypertension: for the treatment of hypertension, either alone or in combination with diuretics, beta-adrenergic blocking agents, calcium chanel blockers, or angiotensin-converting enzyme inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

idt australia ltd - doxazosin mesilate, quantity: 4.852 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; iron oxide red; microcrystalline cellulose; iron oxide yellow; pregelatinised maize starch; magnesium stearate - benign prostatic hyperplasia: for the treatment of both the urinary outflow obstruction and obstuctive and irritative symptoms associated with bph. hypertension: for the treatment of hypertension, either alone or in combination with diuretics, beta-adrenergic blocking agents, calcium chanel blockers, or angiotensin-converting enzyme inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

idt australia ltd - doxazosin mesilate, quantity: 2.426 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; iron oxide yellow - benign prostatic hyperplasia: for the treatment of both the urinary outflow obstruction and obstuctive and irritative symptoms associated with bph. hypertension: for the treatment of hypertension, either alone or in combination with diuretics, beta-adrenergic blocking agents, calcium chanel blockers, or angiotensin-converting enzyme inhibitors